No Data
No Data
Remegen (09995): The company's A-share stock trading has had abnormal fluctuations, but all of the company's business is currently progressing normally.
Remegen (09995) announced that the company's A shares will be traded on July 8, 9, and 10, 2024...
RemeGen Reports Unusual Share Price Drop
HK stocks saw unusual movement as the biomedical sector rallied, boosted by bullish policies for innovative drugs. There are still multiple catalysts for the sector in the second half of the year.
According to the Wise Money APP, biopharmaceutical stocks rebounded collectively. As of the press release, Remegen (09995) rose by 8.06%, to HKD 14.74; Kexing Biotech-B (06990) rose by 7.46%, to HKD 142.6; Genscript Biotech (01548) rose by 5.08% to HKD 9.52, and Junshi Bio (01877) rose by 4.17% to HKD 13. News-wise, on July 5th, the State Council's executive meeting reviewed and approved the "Implementation Plan for Supporting the Development of Innovative Drugs throughout the Entire Chain." Previously, the National Medical Insurance Bureau released the "First Launch Price of New Marketed Chemical Drugs".
Hong Kong stock market anomaly | Remegen (09995) rebounds more than 7%. The company states that all operations are proceeding normally. The controlling shareholder plans to increase shareholding by up to 20 million Chinese yuan.
Remegen (09995) rebounded more than 7% and as of press time, rose 7.04%, at HKD 14.6, with a turnover of HKD 18.1965 million.
Remegen (09995.HK) stocks are experiencing abnormal fluctuations in trading, but all business operations of the company are currently progressing normally.
On July 10th, Gelunhui announced that the closing price of Remegen's (09995.HK) stocks had deviated from the expected value by more than 30% for three consecutive trading days, from July 8th to July 10th, 2024. This is considered an abnormal fluctuation in stock trading according to the relevant provisions of the Shanghai Stock Exchange Trading Rules and the Science and Technology Innovation Board Stock Abnormal Trading Real-time Monitoring Measures. Market rumors suggest that the progress of some of the company's products authorized for external use did not meet expectations. However, according to the company's self-inspection, all of its businesses are proceeding normally, and do not involve any hot concepts in the market. After further verification, the company did not find any other issues.
The market cap of the two cities evaporated by over 10 billion yuan. What happened to Remegen (09955, 688331.SH)?
Both industry-level and company-level bullish news seems to have no effect on Remegen (09955, 688331.SH). From the industry perspective, the recently released "Implementation Plan for Supporting the Development of Innovative Drugs throughout the Whole Industry Chain" proposes to strengthen policy guarantees throughout the whole industry chain, coordinate and utilize policies such as price management, medical insurance payment, commercial insurance, pharmaceutical procurement and use, investment and financing, optimize the evaluation and approval process and medical institution assessment mechanism, and jointly promote the breakthrough and development of innovative drugs; mobilize resources for scientific and technological innovation in all aspects, strengthen basic research in new drug development, and consolidate the foundation of China's innovative drug development. So far, Beijing, Guangzhou, Zhuhai and other places have successively issued
No Data